Fennec Pharma Report issue

For profit Phase 1 Phase 2
Founded: Raleigh NC United States (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
2005
NCT00265057
First Marketed Drug
2022
sodium thiosulfate
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Fennec Pharma | FENNEC PHARMS INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Biliary Tract Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Cholangiocarcinoma (Phase 1)

Colorectal Neoplasms (Phase 1)

Gallbladder Neoplasms (Phase 1)

Klatskin Tumor (Phase 1)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 11